Triomics, an oncology AI company helping cancer centers operationalize complex clinical information, today announced it has raised $22 million in Series B financing led by Battery Ventures, with participation from existing investors Nexus Venture Partners, Lightspeed and Y Combinator, alongside strategic backers Oncology Ventures and Precision Health Informatics, a wholly-owned subsidiary of Texas Oncology. This round brings Triomics’ total funding raised to date to more than $36 million.
The new capital will be used to accelerate adoption across health systems, oncology networks and life sciences organizations; grow Triomics’ AI/engineering and forward-deployed teams; and advance the company’s AI agents for clinical care and research. Triomics is already working with leading cancer centers like Memorial Sloan Kettering Cancer Center (MSK), MD Anderson, Yale Cancer Center and its partner Smilow Cancer Hospital, and Mount Sinai Tisch Cancer Center, as well as some of the nation’s largest community oncology practices, such as Texas Oncology.
Read the full Press Release at Triomics
About Triomics
Triomics is an oncology AI company building the infrastructure that turns complex, longitudinal cancer records into structured, explainable intelligence. The company’s platform supports patient trial matching, pre-visit chart prep, and oncology data abstraction, helping care teams, research teams, and health systems act faster on the information already in the chart. Headquartered in New York, Triomics is backed by Battery Ventures, Lightspeed, Nexus Venture Partners, Y Combinator and Oncology Ventures. For more information, visit www.triomics.com.